ArticleHaematologica2022
Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19.
Abstract read
In one paragraph
Article in Haematologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients.Haematologica · 2023Trial
- Review
- Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era.The Journal of antimicrobial chemotherapy · 2026Review
- Prolonged SARS-CoV-2 infection in hematologic malignancies: clinical impact, risk factors and intra-host viral evolution.Frontiers in immunology · 2026Observational
- Chemotherapy and anti-CD20 monoclonal antibody impact on SARS-CoV-2 nucleic acid amplification tests in hematologic malignancies: a retrospective study.BMC infectious diseases · 2025Observational
- Viral viability markers of SARS-CoV-2: a comparison of cell culture, genomic RNA RT-PCR, and subgenomic RNA RT-PCR.Microbiology spectrum · 2025Article
- Co-infections during SARS-CoV-2 infection in hematologic patients and cell therapy recipients in the omicron era: a Spanish hematopoietic stem cell transplantation and cell therapy group study.BMC infectious diseases · 2025Article
- Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals.Advances in therapy · 2025Review
- Reply to the Comment on: "Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry".Haematologica · 2024Article
- Outcomes of Antiviral Retreatment for Immunocompromised Hosts With Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Polymerase Chain Reaction Positivity: A Multicenter Australian Retrospective Case Series.Open forum infectious diseases · 2024Article
- Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies.Influenza and other respiratory viruses · 2024Article
- Clinical and immunological characteristics of prolonged SARS-CoV-2 Omicron infection in hematologic disease.Blood cancer journal · 2023Article
- Longitudinal analysis of the evolution of cellular immunity to SARS-CoV-2 induced by infection and vaccination.Haematologica · 2023Article
- Treatment of COVID-19 during the Acute Phase in Hospitalized Patients Decreases Post-Acute Sequelae of COVID-19.Journal of clinical medicine · 2023Article
- Prevalence and Clinical Outcome of Omicron Breakthrough Infection in Patients With Hematologic Disease: A Prospective Observational Cohort Study.HemaSphere · 2023Article
- Successful CAR-T cell therapy in a refractory MCL patient with bacterial, fungal and COVID-19 infection: a case report.Frontiers in transplantation · 2023Article
- Assessing the Efficacy of Early Therapies against SARS-CoV-2 in Hematological Patients: A Real-Life Study from a COVID-19 Referral Centre in Northern Italy.Journal of clinical medicine · 2022Article
- The Burden of COVID-19 in Adult Patients With Hematological Malignancies: A Single-center Experience After the Implementation of Mass-vaccination Programs Against SARS-CoV-2.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Carolina Garcia-VidalDepartment of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona. carolgv75@hotmail.com.
Pedro Puerta-AlcaldeDepartment of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona.
Aina MateuDepartment of Internal Medicine, Hospital Universitari Mutua Terrassa, Terrassa.
Genoveva Cuesta-ChascoDepartment of Microbiology, Hospital Clinic of Barcelona, Barcelona.
Fernanda MeiraDepartment of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona.
Carlos LoperaDepartment of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona.
Patricia MonzoDepartment of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona.
Marta Santos-BravoDepartment of Microbiology, Hospital Clinic of Barcelona, Barcelona.
Gerard DuenasDepartment of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona.
Mariana ChumbitaDepartment of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona.
Nicole Garcia-PoutonDepartment of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona.
Anna GayaDepartment of Hematology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona.
Marta BodroDepartment of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona.
Sabina HerreraDepartment of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona.
Mar MosqueraDepartment of Microbiology, Hospital Clinic of Barcelona, Barcelona.
Francesc Fernandez-AvilesDepartment of Hematology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona.
Jose Antonio MartinezDepartment of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona.
Josep MensaDepartment of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona.
Eva GineDepartment of Hematology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona.
Maria Angeles MarcosDepartment of Microbiology, Hospital Clinic of Barcelona, Barcelona.
Alex SorianoDepartment of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19Hematologic NeoplasmsHospitalizationHumansSARS-CoV-2Virus Replication
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.